Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Comparing ICU Admission Rates of Mild/Moderate COVID-19 Patients Treated with Hydroxychloroquine, Favipiravir, and Hydroxychloroquine plus Favipiravir

Güner et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2020.12.017
Dec 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
ICU admission 77% Improvement Relative Risk HCQ for COVID-19  Güner et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 704 patients in Turkey Lower ICU admission with HCQ (not stat. sig., p=0.16) c19hcq.org Güner et al., J. Infection and Public .., Dec 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Retrospective 824 hospitalized patients in Turkey showing lower ICU admission for HCQ vs. favipiravir.
risk of ICU admission, 77.3% lower, RR 0.23, p = 0.16, treatment 604, control 100, inverted to make RR<1 favor treatment, IPTW multivariate analysis, HCQ vs. favipiravir.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Güner et al., 29 Dec 2020, retrospective, Turkey, peer-reviewed, 23 authors.
This PaperHCQAll
Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
Rahmet Guner, Imran Hasanoglu, Bircan Kayaaslan, Adalet Aypak, Esragul Akinci, Hurrem Bodur, Fatma Eser, Ayse Kaya Kalem, Orhan Kucuksahin, Ihsan Ates, Aliye Bastug, Yasemin Tezer Tekce, Zeynep Bilgic, Fahriye Melis Gursoy, Hatice Nisa Akca, Seval Izdes, Deniz Erdem, Emra Asfuroglu, Habibe Hezer, Hatice Kilic, Musa Cıvak, Sibel Aydogan, Turan Buzgan
Journal of Infection and Public Health, doi:10.1016/j.jiph.2020.12.017
Background: In this study, we aimed to compare the intensive care unit (ICU) admission rate of hospitalized mild/moderate COVID-19 patients treated with hydroxychloroquine (HCQ), favipiravir, and HCQ plus favipiravir. Methods: Single center retrospective designed observational study conducted in Ankara City Hospital. Patients who were hospitalized between March 15, 2020 and June 1, 2020 in COVID-19 inpatient clinics with laboratory confirmed diagnosis of COVID-19 were included in the study. An inverse probability of treatment weighting (IPTW) for multiple treatment groups approach was used to balance the differences in several variables on admission. Results: Among 2441 patients hospitalized with diagnosis of COVID-19 during the study period, 824 were eligible for the analysis. Median age of patients was 42 (18−93 years). Among all, 347 (43.2%) of the patients had mild disease, 470 (56.8%) had pneumonia. Propensity scores ranged from 0.1841 to 0.9381 in the HCQ group, from 0.03643 to 0.29885 in the favipiravir group, and from 0.03542 to 0.56184 in the HCQ plus favipiravir group. After IPTW for multiple treatment groups was applied, all the covariates in the planned propensity score had weighted standardized effect sizes below 10% which were ranged from 0.005 to 0.092. Multivariate analysis of treatment effect (adjusted effect of treatment) was indicated that there is no statistically significant difference between HCQ, favipiravir, and HCQ plus favipiravir treatment. After using combination of SMOTE and Bootstrap resampling approach, we found no statistically significant difference between HCQ and HCQ plus favipiravir groups in terms of ICU admission. However, compared with the HCQ group, ICU admission rate was statistically significantly higher in the favipiravir group. We obtained the similar results after the sensitivity analysis.
Author contributions Concept and design of the study: RG, IH, BK, EA, AKK, FE. Data collection: IH, BK, AA, AKK, FE, OK, YTT, ZB, FMG, HNA. Data analysis: RG, IH, IA, AB, BC, S İ, DE, SA, MC, HB. Interpretation of the data: RG, IH, BK, EA, HH, HK, OK, FE. Drafting the manuscript: RG, IH, TB, BK. Critical revision of the manuscript: IH, BK, AA, EA, SI, DE. All authors approved the final version of the manuscript. Ethical approval The study was approved by the Turkish Ministry of Health and ethics board of Ankara City Hospital (No: E1-20-764). Conflict of interest None to declare.
References
Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2020.06.099
Borba, Val, Sampaio, Alexandre, Melo et al., Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial, JAMA Netw Open, doi:10.5582/bst.2020.01047
Cai, Yang, Liu, Chen, Shu et al., Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering, doi:10.1016/j.tmaid.2020.101791
Catteau, Dauby, Montourcy, Bottieau, Hautekiet et al., Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants, Int J Antimicrob Agents, doi:10.1016/j.ijid.2020.06.099
Covid-, Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: findings from the observational multicentre Italian CORIST study, Eur J Intern Med, doi:10.1016/j.ijantimicag.2020.106144
Doi, Hibino, Hase, Yamamoto, Kasamatsu et al., A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19, Antimicrob Agents Chemother, doi:10.1016/j.ejim.2020.08.019
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med, doi:10.1128/AAC.01897-20
Huang, Tang, Pang, Li, Ma et al., Treating COVID-19 with chloroquine, J Mol Cell Biol, doi:10.1136/bmj.m2328
Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial, Clin Infect Dis, doi:10.1093/cid/ciaa1176
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis, Travel Med Infect Dis, doi:10.1093/jmcb/mjaa014
Lumley, survey: analysis of complex survey samples, R package version
Mitjà, Corbacho-Monné, Ubals, Tebe, Ñafiel et al., Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial, Clin Infect Dis, doi:10.1093/cid/ciaa1176
Ridgeway, Mccaffrey, Morral, Griffin, Burgette et al., Twang: Toolkit for weighting and analysis of nonequivalent groups
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State, JAMA, doi:10.1093/cid/ciaa1009
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ, doi:10.1001/jamanetworkopen.2020.8857
Walter, Practical propensity score methods using R
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1001/jama.2020.8630
Yee, VGAM: Vector Generalized Linear and Additive Models
{ 'indexed': {'date-parts': [[2024, 3, 12]], 'date-time': '2024-03-12T12:24:54Z', 'timestamp': 1710246294017}, 'reference-count': 26, 'publisher': 'Elsevier BV', 'issue': '3', 'license': [ { 'start': { 'date-parts': [[2021, 3, 1]], 'date-time': '2021-03-01T00:00:00Z', 'timestamp': 1614556800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2020, 12, 23]], 'date-time': '2020-12-23T00:00:00Z', 'timestamp': 1608681600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': { 'domain': [ 'clinicalkey.jp', 'clinicalkey.com', 'clinicalkey.es', 'clinicalkey.fr', 'clinicalkey.com.au', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 3]]}, 'DOI': '10.1016/j.jiph.2020.12.017', 'type': 'journal-article', 'created': { 'date-parts': [[2020, 12, 29]], 'date-time': '2020-12-29T13:04:37Z', 'timestamp': 1609247077000}, 'page': '365-370', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 13, 'title': 'Comparing ICU admission rates of mild/moderate COVID-19 patients treated with ' 'hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir', 'prefix': '10.1016', 'volume': '14', 'author': [ {'given': 'Rahmet', 'family': 'Guner', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-6692-3893', 'authenticated-orcid': False, 'given': 'Imran', 'family': 'Hasanoglu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bircan', 'family': 'Kayaaslan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Adalet', 'family': 'Aypak', 'sequence': 'additional', 'affiliation': []}, {'given': 'Esragul', 'family': 'Akinci', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hurrem', 'family': 'Bodur', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fatma', 'family': 'Eser', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ayse', 'family': 'Kaya Kalem', 'sequence': 'additional', 'affiliation': []}, {'given': 'Orhan', 'family': 'Kucuksahin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ihsan', 'family': 'Ates', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-8831-4877', 'authenticated-orcid': False, 'given': 'Aliye', 'family': 'Bastug', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yasemin', 'family': 'Tezer Tekce', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zeynep', 'family': 'Bilgic', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fahriye Melis', 'family': 'Gursoy', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hatice Nisa', 'family': 'Akca', 'sequence': 'additional', 'affiliation': []}, {'given': 'Seval', 'family': 'Izdes', 'sequence': 'additional', 'affiliation': []}, {'given': 'Deniz', 'family': 'Erdem', 'sequence': 'additional', 'affiliation': []}, {'given': 'Emra', 'family': 'Asfuroglu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Habibe', 'family': 'Hezer', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hatice', 'family': 'Kilic', 'sequence': 'additional', 'affiliation': []}, {'given': 'Musa', 'family': 'Cıvak', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sibel', 'family': 'Aydogan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Turan', 'family': 'Buzgan', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.jiph.2020.12.017_bib0005', 'unstructured': '“Solidarity” clinical trial for COVID-19 treatments ' 'https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments ' '(Accessed 24 June 2020).'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0010', 'unstructured': 'Clinical management of COVID-19 ' 'https://www.who.int/publications-detail-redirect/clinical-management-of-covid-19 ' '(Accessed 24 June 2020).'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0015', 'unstructured': 'What’s new | Coronavirus Disease COVID-19. COVID-19 Treatment Guidelines ' 'n.d. https://www.covid19treatmentguidelines.nih.gov/whats-new/ (Accessed ' '24 June 2020).'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0020', 'doi-asserted-by': 'crossref', 'unstructured': 'Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial ' 'Version 7) (Released by National Health Commission & National ' 'Administration of Traditional Chinese Medicine on March 3, 2020). Chin ' 'Med J 2020;133:1087–95. https://doi.org/10.1097/CM9.0000000000000819.', 'DOI': '10.1097/CM9.0000000000000819'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0025', 'unstructured': 'Rehberler ' 'https://hsgm.saglik.gov.tr/en/covid-19-i-ngilizce-dokumanlar/rehberler.html ' '(Accessed 24 June 2020).'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0030', 'series-title': 'Practical propensity score methods using R', 'author': 'Leite', 'year': '2016'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0035', 'unstructured': 'Thomas W. Yee (2020). VGAM: Vector Generalized Linear and Additive ' 'Models. R package version 1.1-3. ' 'https://CRAN.R-project.org/package=VGAM.'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0040', 'series-title': 'Twang: Toolkit for weighting and analysis of nonequivalent groups', 'author': 'Ridgeway', 'year': '2020'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0045', 'article-title': '“survey: analysis of complex survey samples.”', 'author': 'Lumley', 'year': '2020', 'journal-title': 'R package version 4.0'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0050', 'doi-asserted-by': 'crossref', 'first-page': '396', 'DOI': '10.1016/j.ijid.2020.06.099', 'article-title': 'Treatment with hydroxychloroquine, azithromycin, and combination in ' 'patients hospitalized with COVID-19', 'volume': '97', 'author': 'Arshad', 'year': '2020', 'journal-title': 'Int J Infect Dis'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0055', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijantimicag.2020.106144', 'article-title': 'Low-dose hydroxychloroquine therapy and mortality in hospitalised ' 'patients with COVID-19: a nationwide observational study of 8075 ' 'participants', 'volume': '56', 'author': 'Catteau', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0060', 'doi-asserted-by': 'crossref', 'first-page': '38', 'DOI': '10.1016/j.ejim.2020.08.019', 'article-title': 'Use of hydroxychloroquine in hospitalised COVID-19 patients is ' 'associated with reduced mortality: findings from the observational ' 'multicentre Italian CORIST study', 'volume': '82', 'author': 'COVID-19 RISK and Treatments (CORIST) Collaboration', 'year': '2020', 'journal-title': 'Eur J Intern Med'}, { 'issue': '12', 'key': '10.1016/j.jiph.2020.12.017_bib0065', 'doi-asserted-by': 'crossref', 'DOI': '10.1128/AAC.01897-20', 'article-title': 'A prospective, randomized, open-label trial of early versus late ' 'favipiravir in hospitalized patients with COVID-19', 'volume': '64', 'author': 'Doi', 'year': '2020', 'journal-title': 'Antimicrob Agents Chemother'}, { 'issue': '25', 'key': '10.1016/j.jiph.2020.12.017_bib0070', 'doi-asserted-by': 'crossref', 'first-page': '2411', 'DOI': '10.1056/NEJMoa2012410', 'article-title': 'Observational study of hydroxychloroquine in hospitalized patients with ' 'Covid-19', 'volume': '382', 'author': 'Geleris', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0075', 'article-title': 'AVIFAVIR for treatment of patients with moderate COVID-19: interim ' 'results of a phase II/III multicenter randomized clinical trial', 'author': 'Ivashchenko', 'year': '2020', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0080', 'article-title': 'Hydroxychloroquine for early treatment of adults with mild Covid-19: a ' 'randomized-controlled trial', 'author': 'Mitjà', 'year': '2020', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0085', 'doi-asserted-by': 'crossref', 'first-page': '2493', 'DOI': '10.1001/jama.2020.8630', 'article-title': 'Association of treatment with hydroxychloroquine or azithromycin with ' 'in-hospital mortality in patients with COVID-19 in New York State', 'volume': '323', 'author': 'Rosenberg', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0090', 'doi-asserted-by': 'crossref', 'first-page': '269', 'DOI': '10.1038/s41422-020-0282-0', 'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged ' 'novel coronavirus (2019-nCoV) in vitro', 'volume': '30', 'author': 'Wang', 'year': '2020', 'journal-title': 'Cell Res'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0095', 'doi-asserted-by': 'crossref', 'first-page': '72', 'DOI': '10.5582/bst.2020.01047', 'article-title': 'Breakthrough: chloroquine phosphate has shown apparent efficacy in ' 'treatment of COVID-19 associated pneumonia in clinical studies', 'volume': '14', 'author': 'Gao', 'year': '2020', 'journal-title': 'Biosci Trends'}, { 'issue': '4', 'key': '10.1016/j.jiph.2020.12.017_bib0100', 'doi-asserted-by': 'crossref', 'first-page': 'e208857', 'DOI': '10.1001/jamanetworkopen.2020.8857', 'article-title': 'Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive ' 'Therapy for Patients Hospitalized With Severe Acute Respiratory ' 'Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical ' 'Trial', 'volume': '3', 'author': 'Borba', 'year': '2020', 'journal-title': 'JAMA Netw Open'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0105', 'article-title': 'Hydroxychloroquine in patients with mainly mild to moderate coronavirus ' 'disease 2019: open label, randomised controlled trial', 'volume': '369', 'author': 'Tang', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0110', 'article-title': 'Clinical efficacy of hydroxychloroquine in patients with covid-19 ' 'pneumonia who require oxygen: observational comparative study using ' 'routine care data', 'volume': '369', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0115', 'doi-asserted-by': 'crossref', 'first-page': '322', 'DOI': '10.1093/jmcb/mjaa014', 'article-title': 'Treating COVID-19 with chloroquine', 'volume': '12', 'author': 'Huang', 'year': '2020', 'journal-title': 'J Mol Cell Biol'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0120', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.tmaid.2020.101791', 'article-title': 'Outcomes of 3,737 COVID-19 patients treated with ' 'hydroxychloroquine/azithromycin and other regimens in Marseille, ' 'France: a retrospective analysis', 'volume': '36', 'author': 'Lagier', 'year': '2020', 'journal-title': 'Travel Med Infect Dis'}, { 'issue': '10', 'key': '10.1016/j.jiph.2020.12.017_bib0125', 'first-page': '1192', 'article-title': 'Experimental treatment with favipiravir for COVID-19: an open-label ' 'control study', 'volume': '6', 'author': 'Cai', 'year': '2020', 'journal-title': 'Engineering (Beijing)'}, { 'key': '10.1016/j.jiph.2020.12.017_bib0130', 'unstructured': 'Covid-19 Living Data n.d. ' 'https://covid-nma.com/living_data/infos_participants.php?i=54 (accessed ' '15 October 2020).'}], 'container-title': 'Journal of Infection and Public Health', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1876034120307735?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1876034120307735?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2021, 3, 25]], 'date-time': '2021-03-25T14:39:10Z', 'timestamp': 1616683150000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1876034120307735'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 3]]}, 'references-count': 26, 'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2021, 3]]}}, 'alternative-id': ['S1876034120307735'], 'URL': 'http://dx.doi.org/10.1016/j.jiph.2020.12.017', 'relation': {}, 'ISSN': ['1876-0341'], 'subject': [ 'Infectious Diseases', 'Public Health, Environmental and Occupational Health', 'General Medicine'], 'container-title-short': 'Journal of Infection and Public Health', 'published': {'date-parts': [[2021, 3]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Comparing ICU admission rates of mild/moderate COVID-19 patients treated with ' 'hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'Journal of Infection and Public Health', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.jiph.2020.12.017', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2021 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin ' 'Abdulaziz University for Health Sciences.', 'name': 'copyright', 'label': 'Copyright'}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit